Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors
Study Details
Study Description
Brief Summary
Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th stimulation day until ovulation induction with a bolus of another injection of a gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception, avoiding the LH surge. It has been described the usefulness of orally administered medroxyprogesterone acetate, 10 mg to inhibit the endogenous LH surge in IVF patients during COS.
In donors, by administering a single injection of FSH-CTP and oral desogestrel since the first menstruation day, the total number of injections administered is reduced and less discomfort is experienced without adverse impact on ovarian response. No description of the hormonal and ovarian response under this protocol has been published
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
-
oral desogestrel since the first menstruation day,
-
a single injection of FSH-CTP on the 7th menstrual cycle day
-
routine monitoring of ovarian response with transvaginal ultrasound every second day until pre-ovulatory bolus of GnRH
-
Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)
-
Quality of Life questionnaire the day after the bolus
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: FSH-CTP + DESOGESTREL Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation |
Drug: FSH-CTP + DESOGESTREL
Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)
- Quality of Life questionnaire the day after the bolus
|
Outcome Measures
Primary Outcome Measures
- Total dose of gonadotrophins [At the end of the stimulation treatment period (5 or 7 days after begining of treatment)]
Total Consume of gonadotrophins
Secondary Outcome Measures
- Plasma LH [Day of GnrH bolus]
Level of LH in plasma (mIU/ml)
- Number of mature oocytes [Day of oocyte recovery]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Population: donors (18-35 ) from candidates of Donor program
-
Fulfilling inclusión medical and legal criteria (RD -Ley de transposición de la normativa europea a la legislación española 9/2014)
-
Who had had undergone previously convencional COS (controlled ovarian stimulation) with FSH-CTP and daily antagonist injections
-
Given signed consent form.
Exclusion Criteria:
-
Previous low response to COS
-
Previous ovarian hyperstimulation syndrome.
-
Ovarian cysts.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Quiron Dexeus | Barcelona | Spain | 08028 |
Sponsors and Collaborators
- Institut Universitari Dexeus
- Fundación Dexeus Salud de la Mujer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod. 2006 Aug;21(8):2121-5. Epub 2006 Apr 21.
- Martínez F, Clua E, Santmartí P, Boada M, Rodriguez I, Coroleu B. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. Fertil Steril. 2010 Nov;94(6):2433-6. doi: 10.1016/j.fertnstert.2010.02.059. Epub 2010 Apr 28.
- Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M, García-Velasco JA. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013 Mar;26(3):253-9. doi: 10.1016/j.rbmo.2012.11.015. Epub 2012 Dec 5.
- SMD-DES-2016-01